Bioorganic and Medicinal Chemistry Letters

Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals.  64. 2022

A small diversity library of α-methyl amide analogs of sulindac for probing anticancer structure-activity relationships.  28:2136-2142. 2018

Diverse amide analogs of sulindac for cancer treatment and prevention.  27:4614-4621. 2017

Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.  27:1731-1736. 2017

Repurposing of Proton Pump Inhibitors as first identified small molecule inhibitors of endo-β-N-acetylglucosaminidase (ENGase) for the treatment of NGLY1 deficiency, a rare genetic disease.  27:2962-2966. 2017

Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.  26:1237-1244. 2016

Hydroxychalcone inhibitors of Streptococcus mutans glucosyl transferases and biofilms as potential anticaries agents.  26:3508-3513. 2016

Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer's disease.  26:5573-5579. 2016

Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease..  24:1472-1478. 2014

Synthesis and SAR of geminal substitutions at the C5′ carbosugar position of pyrimidine-derived HCV inhibitors.  22:6967-6973. 2012

Synthesis and SAR of pyridothiazole substituted pyrimidine derived HCV replication inhibitors.  22:5652-5657. 2012

Pyridofuran substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.  22:5144-5149. 2012

5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors.  22:3229-3234. 2012

Novel substituted pyrimidines as HCV replication (replicase) inhibitors.  22:1160-1164. 2012

Discovery of a new molecular probe ML228: An activator of the hypoxia inducible factor (HIF) pathway.  22:76-81. 2012

Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors.  21:5528-5532. 2011

Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs).  19:2001-2005. 2009

Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A.  18:380-385. 2008

Synthesis of symmetrical C- and pseudo-symmetrical O-linked disaccharide analogs for arabinosyltransferase inhibitory activity in Mycobacterium tuberculosis.  17:4527-4530. 2007

Analogs of the marine alkaloid makaluvamines: Synthesis, topoisomerase II inhibition, and anticancer activity.  17:2890-2893. 2007

Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis.  16:4743-4747. 2006

A new 2-carbamoyl pteridine that inhibits mycobacterial FtsZ.  14:3161-3164. 2004

Activation and desensitization of heteromeric neuronal nicotinic receptors: Implications for non-synaptic transmission.  14:1897-1900. 2004

Heterocyclic aminopyrrolidine derivatives as melatoninergic agents..  13:4381-4384. 2003

Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain.  13:1475-1478. 2003

Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamine.  12:3379-3382. 2002

Synthesis of an arabinofuranosyl disaccharide photoaffinity probe for arabinosyltransferase activity in Mycobacterium tuberculosis.  12:2749-2752. 2002

An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology.  11:2393-2396. 2001

Stereoselective binding of an enantiomeric pair of stromelysin-1 inhibitors caused by conformational entropy factors.  10:2427-2430. 2000

Salicylamide inhibitors of influenza virus fusion.  10:1649-1652. 2000

Preparation and use of a photoactivatable glucose-6-phosphate analogue.  10:535-539. 2000

Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping (vol 9, pg 1901, 1999).  9:3259-3259. 1999

Erratum: Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping (Bioorg. Med. Chem. Lett. (1999) 9 (1901) PII: S0960894X99003182).  9:3259. 1999

Novel quinolizidine salicylamide influenza fusion inhibitors.  9:2177-2180. 1999

Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.  9:1901-1906. 1999

Uridine phosphorylase inhibitors: Chemical modification of benzyloxybenzyl-barbituric acid and its effects on UrdPase inhibition.  9:1477-1480. 1999

Homologated aza analogs of arabinose as antimycobacterial agents.  8:237-242. 1998

Conformationally constrained precursors to retinoic acid analogs which stabilize the 9Z-configuration.  5:953-958. 1995